PZ0042
Sulopenem
≥97% (HPLC)
别名:
(5R,6S)-6-[(1R)-1-Hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, CP-70429
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
Assay:
≥97% (HPLC)
Form:
powder
assay
≥97% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
shipped in
dry ice
storage temp.
−20°C
SMILES string
O=C(O)C1=C(S[C@@H]2C[S@+]([O-])CC2)S[C@@]3([H])N1C([C@]3([H])[C@H](O)C)=O
InChI
1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)/t5-,6?,7+,10-,21?/m1/s1
InChI key
FLSUCZWOEMTFAQ-JNCILSLHSA-N
Biochem/physiol Actions
Sulopenem, formerly CP-70,429, is stable to renal dehydropeptidase I and hydrolytic activity of AmpC β-lactamases and extended-spectrum β-lactamases (ESBLs) that convey resistance to third-generation cephalosporins. This action of sulopenem helps to act against urgent drug-resistant antimicrobial threats, including ESBL-producing Enterobacteriaceae. Sulopenem is effective than ciprofloxacin for treating urogenital upper urinary tract infection (uUTI) in adult women due to quinolone non-susceptible pathogens.
Orally available penem antibiotic to treat Gram-negative multi-drug resistant infections
Sulopenem is an orally available penem antibiotic designed to treat Gram-negative multi-drug resistant infections. It can be administered as an intravenous preparation, and it is also orally available.
存储类别
11 - Combustible Solids
wgk
WGK 3